Methodology to Assess Clinical Liver Safety Data

被引:26
作者
Merz, Michael [1 ]
Lee, Kwan R. [2 ]
Kullak-Ublick, Gerd A. [1 ,3 ]
Brueckner, Andreas [4 ]
Watkins, Paul B. [5 ,6 ,7 ,8 ]
机构
[1] Novartis Inst BioMed Res, Discovery & Invest Safety, CH-4057 Basel, Switzerland
[2] GlaxoSmithKline, Med Analyt, Collegeville, PA USA
[3] Univ Zurich Hosp, Dept Clin Pharmacol & Toxicol, CH-8091 Zurich, Switzerland
[4] Novartis Pharma AG, Basel, Switzerland
[5] Hamner Univ North Carolina, Inst Drug Safety Sci, Res Triangle Pk, NC USA
[6] Univ N Carolina, Sch Med, Chapel Hill, NC USA
[7] Univ N Carolina, Sch Pharm, Chapel Hill, NC USA
[8] Univ N Carolina, Sch Publ Hlth, Chapel Hill, NC USA
关键词
BIOMARKERS;
D O I
10.1007/s40264-014-0184-5
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Analysis of liver safety data has to be multivariate by nature and needs to take into account time dependency of observations. Current standard tools for liver safety assessment such as summary tables, individual data listings, and narratives address these requirements to a limited extent only. Using graphics in the context of a systematic workflow including predefined graph templates is a valuable addition to standard instruments, helping to ensure completeness of evaluation, and supporting both hypothesis generation and testing. Employing graphical workflows interactively allows analysis in a team-based setting and facilitates identificatio\n of the most suitable graphics for publishing and regulatory reporting. Another important tool is statistical outlier detection, accounting for the fact that for assessment of Drug-Induced Liver Injury, identification and thorough evaluation of extreme values has much more relevance than measures of central tendency in the data. Taken together, systematical graphical data exploration and statistical outlier detection may have the potential to significantly improve assessment and interpretation of clinical liver safety data. A workshop was convened to discuss best practices for the assessment of drug-induced liver injury (DILI) in clinical trials.
引用
收藏
页码:S33 / S45
页数:13
相关论文
共 23 条
[1]  
[Anonymous], PICTURE IS WORTH 100
[2]  
[Anonymous], 1994, ELEMENTS GRAPHING DA
[3]   Reexamining transaminase elevation in Phase I clinical trials: the importance of baseline and change from baseline [J].
Cai, Zhaohui ;
Christianson, Anastasia M. ;
Stahle, Lars ;
Keisu, Marianne .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 65 (10) :1025-1035
[4]  
Cleveland WS, 1993, VISUALIZING DATA
[5]  
Crowe B, 2011, CORE ANAL PROGRAM LE
[6]   The Mahalanobis distance [J].
De Maesschalck, R ;
Jouan-Rimbaud, D ;
Massart, DL .
CHEMOMETRICS AND INTELLIGENT LABORATORY SYSTEMS, 2000, 50 (01) :1-18
[7]   Variability in the Upper Limit of Normal for Serum Alanine Aminotransferase Levels: A Statewide Study [J].
Dutta, Anand ;
Saha, Chandan ;
Johnson, Cynthia S. ;
Chalasani, Naga .
HEPATOLOGY, 2009, 50 (06) :1957-1962
[8]  
Gelperin K, 2008, SIMPLE GRAPHIC TOOL
[9]   TRUNCATED ROBUST DISTANCE FOR CLINICAL LABORATORY SAFETY DATA MONITORING AND ASSESSMENT [J].
Lin, Xiwu ;
Parks, Daniel ;
Zhu, Lei ;
Curtis, Lloyd ;
Steel, Helen ;
Rut, Andrew ;
Mooser, Vincent ;
Cardon, Lon ;
Menius, Alan ;
Lee, Kwan .
JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2012, 22 (06) :1174-1192
[10]  
Lin XW, 2012, DRUG SAFETY, V35, P865, DOI 10.2165/11632670-000000000-00000